Yu. G. Sandler

Yu. G. Sandler

Auto-generated profile, based on publicly available information

Yu. G. Sandler

Loginov Moscow Clinical Scientific Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
SBSergey Batskikh
Sergey Batskikh
SMSergey Morozov
Sergey Morozov
EVElena Vinnitskaya
Elena Vinnitskaya
ESEvgeniya Sbikina
Evgeniya Sbikina
ZBZanna Borunova
Zanna Borunova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov

3 September 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AAA. V. Anisonyan
A. V. Anisonyan
YSYu. G. Sandler
Yu. G. Sandler
TKT. Yu. Khaimenova
T. Yu. Khaimenova
VKV. A. Keyan
V. A. Keyan
KSK. G. Saliev
K. G. Saliev
ВВВинницкая Елена Владимировна
Винницкая Елена Владимировна
Aim. To evaluate the frequency of liver fibrosis progression to stage 34 among patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes and obesity, to identify predictors of severe liver fibrosis, to propose an algorithm for diagnosing fibrosis in this category of patients. Materials and methods. 160 patients with NAFLD, type 2 diabetes mellitus (DM) and obesity and 50 patients with NAFLD without diabetes were comprehensively examined. Patients underwent laboratory examination (clinical blood test, biochemical analysis, immunoglobulins G, M, autoantibody assay, coagulogram), liver ultrasound. All patients underwent determination of the liver fibrosis stage by two methods: the serological test FibroMax and indirect ultrasound elastometry of the liver; 40 patients underwent a liver biopsy. Statistical data processing was performed using the programming language and statistical calculations R: we used correlation analysis, multiple logistic regression method, one-way analysis of variance, multi-factor analysis, the Kruskal-Wallis method, and comparison of the number of patients using the Fisher test. Results. DM is a risk factor for the liver fibrosis progression in patients with NAFLD. Significant markers of severe fibrosis in this category of patients are increased levels of GGTP, haptoglobin and alpha-2-macroglobulin, lower platelet and prothrombin levels. Obesity and isolated steatosis without steatohepatitis are not markers of severe liver fibrosis at present, but obesity can be considered a risk factor for the progression of fibrosis in the future. Conclusion. All patients with NAFLD in combination with diabetes need screening to detect advanced liver fibrosis: it is advisable to determine the levels of GGTP, haptoglobin and alpha-2-macroglobulin.

30 March 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ESE S Sbikina
E S Sbikina
EVE V Vinnitskaya
E V Vinnitskaya
SBS N Batskikh
S N Batskikh
YSY G Sandler
Y G Sandler
KSK G Saliev
K G Saliev
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
Background. Despite the well-studied pathogenesis, the etiology of autoimmune liver disease (AILD) remains unknown. Aim. To determine the significance of hepatitis A, B, C and E viruses in the development and progression of AILD. Materials and methods. A single-center case-control study included 139 patients with AILD: autoimmune hepatitis AIH (n=46), primary biliary cholangitis PBS (n=74), primary sclerosing cholangitis PSC (n=19). Median age 56 years, IQR 4865 years. 125 patients without liver disease control group (median age 55 years, IQR 4665 years). Testing of blood serum samples for anti-HAV IgG, anti-HEV IgG, HBsAg, anti-HBc IgG, anti-HCV was carried out by solid-phase ELISA. All patients underwent fibroelastography. Needle liver biopsy 70 patients: AIH (n=37), PBC (n=28) and PSC (n=5). Results. Ab(IgG) to HAV and HBV were detected in patients with AILD significantly more often than in the control group (74.8% vs 54.4%; p0.001). An increased risk of developing AILD was established in patients with the presence of antibodies to HAV, HBV and HEV (OR 2.491, CI 95% [1.4814.190]). The highest risk of developing PBC was found in patients with antibodies to HAV and HBV (OR 3.008, 95% CI [1.6335.542] and OR 2.515, 95% CI [1.2425.093]). In patients with severe liver fibrosis (F3F4 according to METAVIR), antibodies to HAV and HBV were detected significantly more often than in patients with F0F2 [85% vs 65%; p=0.008]. Conclusion. In our work, we have demonstrated the relationship of past hepatitis A, B, E and AILD, as well as the high risk of developing severe fibrosis in patients with AILD and markers of hepatitis A and B viruses indicates the possible involvement of these viruses in the pathogenesis of AILD.

14 September 2020 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
SBS. N. Batskikh
S. N. Batskikh
EVE. V. Vinnitskaya
E. V. Vinnitskaya
ESE. S. Sbikina
E. S. Sbikina
ZBZh. V. Borunova
Zh. V. Borunova
Aleksey DorofeevAleksey Dorofeev
Aleksey Dorofeev
YSYu. G. Sandler
Yu. G. Sandler
Риск развития цирроза у пациентов с неалкогольной жировой болезнью печени, перенесших вирусный гепатит В

1 January 2023
Verified
Journal Article
Closed access
EAE.N. Aleksandrova
E.N. Aleksandrova
ADA.S. Dorofeev
A.S. Dorofeev
ANA.A. Novikov
A.A. Novikov
YSYu.G. Sandler
Yu.G. Sandler

22 December 2019 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YSYu. G. Sandler
Yu. G. Sandler
EVE. V. Vinnitskaya
E. V. Vinnitskaya
KSK. G. Saliev
K. G. Saliev
SKSERGEY KHOMERIKI
SERGEY KHOMERIKI
TКT. Yu. Кhaimenova
T. Yu. Кhaimenova
ТХТ. Ю. Хайменова
Т. Ю. Хайменова
Лекарственные поражения печени, индуцированные нестероидными противовоспалительными препаратами: лекция и клиническое наблюдение